Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Silvio Danese MD, PhD

Silvio Danese MD, PhD

Director of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Professor of Medicine of University Vita-Salute San Raffaele, Italy

Silvio Danese trained in Gastroenterology at Policlinico Gemelli, Rome, and earned a PhD during his research at Case Western Reserve University, Cleveland, Ohio, USA, from 2001 to 2004. His main research focuses on investigating the fundamental mechanisms underlying IBD pathogenesis, while his clinical activities center on IBD service. He is actively involved in numerous international clinical trials in IBD and has authored over 700 publications in leading journals. Since October 2021, he has served as the Head of the Gastroenterology and Gastrointestinal Endoscopy Unit at Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital in Milan, Italy. He is a Past President (2018–2020) of the European Crohn’s and Colitis Organization (ECCO) and a member of various IBD-related organizations. ORCID ID: https://orcid.org/0000-0001-7341-1351.

Disclosures

Silvio Danese has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor.